Section 232 Pharmaceutical Tariff – Effective July 31, 2026

Section 232 pharma tariff takes effect July 31, 2026 with tiered rates affecting branded patented drugs. Generics and biosimilars are excluded under the current proclamation. The tariff replaces Section 122 stack for covered drugs. Industries affected: branded pharma, specialty pharma, certain biological products.

This guide covers Section 232 Pharmaceutical Tariff – Effective July 31, 2026. Section 232 of the Trade Expansion Act of 1962 authorizes tariffs on imports based on national security findings.

For SMB importers, Section 232 exposure depends on HS classification, country of origin, and current effective rate (which has varied through administrative determinations).

Scope – branded patented drugs

Section 232 pharma covers branded patented pharmaceutical products. Specific HTS subheadings in Chapter 30 are listed.

Generics and biosimilars excluded

The current proclamation excludes generics and biosimilars. This excludes most generic-pharma exporters from the new tariff.

Tiered rate structure

Rates vary by category – innovative biologics, small-molecule branded drugs, etc. Specific rate structures published in the proclamation.

Implications for Big Pharma

AstraZeneca, Pfizer Ireland, Lilly, Merck face direct exposure on branded products manufactured outside U.S. Supply chain shifts may not be operationally feasible at scale.

Frequently asked questions

Does Section 232 still apply in 2026?

Yes. Section 232 has no statutory expiration. Steel and aluminum since 2018; copper added 2026; pharma effective July 31, 2026. MedTech and semiconductor investigations in flight.

Does Section 232 stack with Section 122?

Generally no. Section 232-covered goods pay Section 232 in lieu of Section 122. Edge cases exist where finished goods contain Section 232 inputs but are not themselves covered.

Can I file for a Section 232 exclusion?

Specific exclusion processes have applied historically (especially for steel and aluminum). Current exclusion windows vary; we track active processes.

How does Section 232 derivative scope work?

Derivatives expansion brings downstream products into scope at the HTS subheading level. Component-level analysis identifies actual coverage for finished goods.

How do you help with Section 232 work?

Scope analysis, supplier shift modeling, product petition filings, and exclusion request support. Engagements typically $5,000-$15,000 fixed-fee.